TENAX THERAPEUTICS,

TENX
Delayed Quote. Delayed  - 05/13 04:00:00 pm
2.01USD -4.29%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 --
EBITDA -9,86-
Operating profit (EBIT)1 -9,87-12,3
Operating Margin --
Pre-Tax Profit (EBT)1 -9,85-12,2
Net income1 -9,85-12,2
Net margin --
EPS2 -1,33-0,61
Dividend per Share --
Last update 03/31/2021-
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt --
Net Cash position --
Leverage (Debt / EBITDA) --
Free Cash Flow1 -9,2826,7
ROE (Net Profit / Equities) --
Shareholders' equity1 --
ROA (Net Profit / Asset) --
Assets1 --
Book Value Per Share --
Cash Flow per Share --
Capex1 -1,00
Capex / Sales --
Last update 03/31/202104/09/2021
1 USD in Million
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 30 M $ -
Valuation 2021e 2022e
P/E ratio (Price / EPS) -3,32x -18,3x
Capitalization / Revenue - 1,20x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) - 25,0%
Operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) - 11,0%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   - 0,40%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend